Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study

Anxiety and DepressionBipolar Disorder

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment

Int J Bipolar Disord.

Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A

doi: 10.1186/

Migraine and HeadacheAnxiety and Depression

The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study

J Affect Disord.

Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G

doi: 10.1016/

Further Publications Psychiatry

Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study

J Affect Disord

Ishigooka J, Kato T, Miyajima M, Watabe K, Masuda T, Hagi K, Higuchi T

doi: 10.1016/j.jad.2020.12.005

Bipolar DisorderAlcohol Use Disorder (AUD)

Feasibility and acceptability of integrated psychological therapy versus treatment as usual for people with bipolar disorder and co-morbid alcohol use: A single blind randomised controlled trial

J Affect Disord.

Jones SH, Riste L, Robinson H, Holland F, Peters S, Hartwell R, Berry K, Fitzsimmons M, Wilson I, Hilton C, Long R, Bateman L, Weymouth E, Owen R, Roberts C, Barrowclough C

doi: 10.1016/j.jad.

EpilepsyPsychosis and Schizophrenia

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

Lancet Psychiatry.

Kahn RS, Winter van Rossum , Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group

doi: 10.1016/

Aging and Cognitive FunctionsMultiple Sclerosis

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

J Neurol.

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group

doi: 10.1007/s00415-017-8642-5.

Aging and Cognitive FunctionsBipolar Disorder

Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: an overview of evidence

Bipolar Disord.

Van Rheenen TE, Lewandowski KE, Bauer IE, Kapczinski F, Miskowiak K, Burdick KE, Balanzá-Martínez V

doi: 10.1111/bdi.12821.

Aging and Cognitive FunctionsDementia

IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia

J Neurol Neurosurg Psychiatry.

Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A

doi: 10.1136/jnnp-2015-311486.

Bipolar Disorder

Bipolar disorder in primary care: a qualitative study of clinician and patient experiences with diagnosis and treatment

Fam Pract.

Cerimele JM, Fortney JC, Pyne JM, Curran GM

doi: 10.1093/fampra/cmy019.

Related content